Bristol-Myers's Recent PD-1 Win Could Have Significant Impact on Earlier Use

Tuesday, September 8, 2015

Source: FierceBiotech

Bristol Myers-Squibb ($BMY), a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.

View All News »